Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
ConclusionIdentification of anti-HBs-negative subgroups is critical to improve the cost-effectiveness of prophylactic antiviral therapy in lymphoma patients with resolved HBV infection.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | Chemotherapy | Databases & Libraries | Endemics | General Medicine | Hepatitis | Hepatitis B | Liver | Lymphoma | Rituxan | Study | Taiwan Health | Urology & Nephrology